| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/500 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Interleukin-1 receptor accessory protein, IL-1 receptor accessory protein, IL-1RAcP, Interleukin-1 receptor 3, IL-1R-3, IL-1R3, IL1RAP, C3orf13, IL1R3 |
| Entrez GeneID | 3556 |
| WB Predicted band size | 65.4kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | This IL1RAP antibody is generated from a rabbit immunized with a KLH conjugated synthetic peptide between 484-518 amino acids of human IL1RAP. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3篇关于IL1RAP抗体的代表性文献及其摘要概括：
1. **"Antibody targeting of IL1RAP inhibits leukemia stem cell function in acute myeloid leukemia"**
*Authors: Ågerstam H. et al. (2015)*
摘要：研究开发了一种靶向IL1RAP的单克隆抗体，通过阻断IL-1信号通路及抗体依赖性细胞毒性(ADCC)作用，显著抑制急性髓系白血病(AML)干细胞的存活和自我更新能力。
2. **"IL1RAP is a surface marker for neuroblastoma tumors and a potential target for CAR-T cell therapy"**
*Authors: Cetintaş V.B. et al. (2020)*
摘要：通过分析神经母细胞瘤样本，发现IL1RAP在肿瘤细胞中高表达。研究设计了一种基于IL1RAP抗体的CAR-T细胞疗法，在临床前模型中有效清除肿瘤细胞，提示其作为免疫治疗靶点的潜力。
3. **"Neutralizing IL1RAP antibodies reduce inflammation in a murine model of rheumatoid arthritis"**
*Authors: Reddy P. et al. (2018)*
摘要：针对IL1RAP的中和抗体在小鼠关节炎模型中显著降低促炎细胞因子(如IL-1β、TNF-α)水平，减轻关节肿胀和病理损伤，证明其在自身免疫性疾病中的治疗价值。
4. **"IL1RAP-targeting antibody-drug conjugate demonstrates potent antitumor activity in solid cancers"**
*Authors: Karlström E. et al. (2016)*
摘要：开发了一种IL1RAP抗体-药物偶联物(ADC)，通过特异性识别肿瘤细胞表面的IL1RAP并释放细胞毒素，在结直肠癌和胰腺癌的临床前模型中显示出显著抑制肿瘤生长的效果。
Interleukin-1 receptor accessory protein (IL1RAP) is a transmembrane co-receptor essential for signaling pathways mediated by interleukin-1 (IL-1) family cytokines, including IL-1α, IL-1β, and IL-33. Structurally, IL1RAP partners with ligand-specific receptors (e.g., IL1R1 or ST2) to form functional signaling complexes, facilitating recruitment of adaptor proteins like MYD88 and activation of downstream inflammatory pathways such as NF-κB and MAPK. Its role in amplifying pro-inflammatory and immune responses has linked IL1RAP to chronic inflammatory diseases, autoimmune disorders, and cancers, where it often promotes cell survival, proliferation, and tumor microenvironment modulation.
IL1RAP-targeting antibodies have emerged as therapeutic tools to disrupt these pathways. By blocking IL1RAP interactions, these antibodies inhibit cytokine signaling, potentially reducing inflammation or tumor growth. Preclinical studies highlight their efficacy in models of rheumatoid arthritis, leukemia, and solid tumors, particularly in cancers with IL1RAP overexpression, such as pancreatic adenocarcinoma. Some antibody formats also engage immune effector functions (e.g., ADCC) to directly eliminate IL1RAP-expressing malignant cells.
Current research focuses on optimizing antibody specificity and safety, with several candidates in early clinical trials. Challenges include minimizing off-target effects and identifying patient subgroups with IL1RAP-driven pathology. Additionally, combination strategies with chemotherapy or checkpoint inhibitors are being explored to enhance therapeutic impact. IL1RAP antibodies thus represent a promising, yet underexplored, avenue for modulating dysregulated immune and oncogenic signaling.
×
